Kabouridis Panagiotis S
Bone and Joint Research Unit, William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1M 6BQ, UK.
Trends Biotechnol. 2003 Nov;21(11):498-503. doi: 10.1016/j.tibtech.2003.09.008.
The impermeable nature of the cell membrane to peptides, proteins, DNA and oligonucleotides limits the therapeutic potential of these biological agents. However, the recent discovery of short cationic peptides that cross the plasma membrane efficiently is opening up new possibilities for the intracellular delivery of such agents. These peptides are commonly referred to as protein transduction domains (PTDs) and are successfully used to transport heterologous proteins, peptides and other types of cargo into cells. Several recent reports have used the membrane transducing technology in vivo to deliver biologically active cargo into various tissues. This review discusses the structure of the most commonly used PTDs and how their ability to transduce membranes is used to regulate biological functions. It also considers future directions and the potential of this technology to move from the laboratory into the clinic.
细胞膜对肽、蛋白质、DNA和寡核苷酸的不可渗透性限制了这些生物制剂的治疗潜力。然而,最近发现的能有效穿过质膜的短阳离子肽为这类制剂的细胞内递送开辟了新的可能性。这些肽通常被称为蛋白质转导结构域(PTDs),并已成功用于将异源蛋白质、肽和其他类型的货物转运到细胞中。最近的几份报告已在体内使用膜转导技术将生物活性货物递送至各种组织。本综述讨论了最常用的PTDs的结构,以及如何利用它们的膜转导能力来调节生物学功能。它还考虑了该技术从实验室走向临床的未来方向和潜力。